Disease activity, damage, comorbidities and treatment at the time of enrolment
| Median SLEDAI | 2 (IQR 0–4) |
| Patients with active disease (SLEDAI >4) | 18.2% |
| Median SLEDAI of active patients | 8 (IQR 6–10) |
| Patients with SLICC-DI >0 | 49.3% |
| Median SLICC-DI (among patients with SLICC-DI >0) | 2 (IQR 1–3) |
| Patients with fibromyalgia Patients on glucocorticoid Median daily prednisone dose (IQR) Patients on hydroxychloroquine Patients on cDMARDs Patients on biologics | 11.8% 54.3% 5 mg (5–5) 77.6% 45.3% 7.2% |
cDMARDs, conventional disease-modifying antirheumatic drugs; SLEDAI, Systemic Lupus Disease Activity Index; SLICC-DI, Systemic Lupus International Collaborating Clinics-Damage Index.